Published in

Springer, Acta Neuropathologica, 5(144), p. 821-842, 2022

DOI: 10.1007/s00401-022-02454-z

Links

Tools

Export citation

Search in Google Scholar

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.

Journal article published in 2022 by Iris E. Jansen, Sven J. van der Lee, John C. van Swieten, Cornelia M. van Duijn, Ris E. Jansen, Wiesje van der Flier, Maria Carolina Dalmasso, Sung Yj, Deleuze Jf, Jansen Ie, Luca Kleineidam, Fahri Kucukali, Fahri Küçükali, Niccolo Tesí, Yun Ju Sung and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractAmyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer’s disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for Aβ42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple Aβ42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume.